| EMA number | EMEA/H/C/004743 |
| ATC code | N07BC01 |
| Authorisation | 19 June 2019 |
| Withdrawn | 19 June 2025 |
| Revision | 6 |
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.